At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, John Gribben, MD, from Barts Cancer Institute, London, UK, discusses how chronic lymphocytic leukemia (CLL) patients could soon benefit from specific treatments based on CLL characterization and their disease biology.